ICOS‐ImmunoPET Monitors T Cell Activation After Combination Immune Checkpoint Blockade in a Mouse Model of Melanoma Brain Metastasis
Open Access
- 15 August 2026
- journal article
- research article
- Published by Wiley in Advanced Science
- Vol. 13 (56) , e76803
Abstract
Immune checkpoint inhibitors (ICIs) have transformed outcomes for melanoma brain metastases (MBM), yet early response assessment remains challenging because currently available tools such as magnetic resonance imaging (MRI) lack molecular specificity and are confounded by pseudoprogression. Antibody‐based positron emission tomography (immunoPET) is a highly sensitive and specific molecular imaging technique that enables noninvasive, whole‐body visualization of immune dynamics in vivo. The inducible T cell costimulatory receptor (ICOS) is a promising biomarker of therapy‐induced T cell activation. Here, a previously validated tracer, [ 89 Zr]DFO‐ICOS mAb, is used to track activated T cells in a murine MBM model treated with combined anti‐PD‐1/anti‐CTLA‐4 therapy, and immunoPET signal is shown to correspond with therapeutic response and intratumoral T cell activation. To establish clinical relevance of ICOS‐immunoPET, single‐cell RNA sequencing data from 6 human MBM specimens are reanalyzed, revealing significantly higher ICOS expression accompanied by coordinated activation signatures in ICI‐treated tumors. These findings support ICOS‐immunoPET as a promising strategy for earlier, noninvasive, functionally informative assessment of immunotherapy response, with potential to improve patient stratification in brain metastases.Keywords
Funding Information
- National Institutes of Health (R01CA286998‐03)
- National Institutes of Health (U54CA261717)
- National Science Foundation (DGE‐2146755)
This publication has 27 references indexed in Scilit:
- Mechanisms of immune checkpoint inhibitor-mediated liver injuryActa Pharmaceutica Sinica B, 2021
- Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)Neuro-Oncology, 2021
- Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogressionNeuro-Oncology, 2019
- Cell Detection with Star-Convex Polygons2018
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainNew England Journal of Medicine, 2018
- Anti–PD-1/anti–CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+T cell traffickingProceedings of the National Academy of Sciences, 2018
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2017
- Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based studyNeuro-Oncology, 2017
- [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activityProceedings of the National Academy of Sciences, 2016
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial GliomasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013